Medroxyprogesterone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names: Medroxyprogesteronum, Medroxyprogesteron acetate, Medroxyprogesteron, Medroxiprogesteronum, Medroxiprogesterona, Medrossiprogesterone, Medroprogesterone Acetate, MAP, Hydroxymethylprogesterone, CBP-1011, Aragest, Aragest 5, Asconale, Clinofem, Clinovir, Colirest, DMPA, Depo-Clinovir, Depo-Prodasone, Depo-Progestin, Depo-Promone, Depot-Medroxyprogesterone acetate, Farlutal, Farlutin, G-Farlutal, Gestapuran, Hematrol, Hysron, Indivina, Lunelle, Lutopolar, Lutoral, Med-Pro, Meprate, Metigestrona, MPA Gyn 5, Nadigest, Nidaxin, Novo-Medrone, Oragest, Perlutex, Perlutex Leo, Prodasone, Progestalfa, Progevera, Proverone, Ralovera, Repromap, Repromix, Sirprogen, Sodelut G, Veramix
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Dosing and Administration
Vasomotor Symptoms / Vulvar and Vaginal Atrophy
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Subsequent dosage adjustment may be made based upon the
individual patient response. In patients where bleeding or spotting remains a problem, after appropriate
evaluation, consideration should be given to changing the dose level. This dose should be periodically
reassessed by the healthcare provider.
Postmenopausal Osteoporosis
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Dosage may be adjusted depending on individual clinical and bone
mineral density responses. This dose should be periodically reassessed by the healthcare provider.
In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration
should be given to changing the dose level. This dose should be periodically reassessed by the
healthcare provider.
PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken
daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and
5 mg of medroxyprogesterone acetate, taken on days 15 through 28.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Medroxyprogesterone
Return to top
Publication Resources
Most Recent Articles on Medroxyprogesterone
Review Articles on Medroxyprogesterone
Articles on Medroxyprogesterone in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Medroxyprogesterone
Return to top
Trial Resources
Ongoing Trials with Medroxyprogesterone at Clinical Trials.gov
Trial Results with Medroxyprogesterone
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Medroxyprogesterone
Cochrane Collaboration on Medroxyprogesterone
Cost Effectiveness of Medroxyprogesterone
Return to top
Media Resources
Powerpoint Slides on Medroxyprogesterone
Images of Medroxyprogesterone
Podcasts & MP3s on Medroxyprogesterone
Videos on Medroxyprogesterone
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Medroxyprogesterone
Discussion Groups on Medroxyprogesterone
Patient Handouts on Medroxyprogesterone
Blogs on Medroxyprogesterone
Medroxyprogesterone in the News
Medroxyprogesterone in the Marketplace
Return to top
International Resources
Medroxyprogesterone en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
